Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$175.75M

FY 2025 · Annual

Investing Cash Flow

$179.99M

FY 2025 · Annual

Financing Cash Flow

$1.09M

FY 2025 · Annual

-99.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(67.49M)109.2M(153.16M)(167.58M)(219.88M)
Depreciation & Amortization53K93K310K306K311K
Deferred Income Tax3.1M0000
Stock-Based Compensation24.38M27.96M30.44M37.82M36.04M
Change in Working Capital(3.54M)11.18M(339K)(389K)14.08M
Accounts Receivables00000
Inventory00000
Accounts Payables(4.84M)(509K)(167K)(812K)(839K)
Other Working Capital1.29M11.69M(172K)423K14.92M
Other Non-Cash Items67K(275.09M)(11.52M)(15.47M)(6.31M)
Operating Cash Flow(43.43M)(126.66M)(134.28M)(145.3M)(175.75M)
Capital Expenditures(589.23K)(1.13M)(208K)0(49K)
Acquisitions (Net)923K275M(36.01K)00
Purchases of Investments(525.81M)(377.92M)(373.38M)(721.13M)(236.53M)
Sales of Investments192.04M352.93M409.4M584.82M416.57M
Other Investing Activities(333.78K)91K36.01K00
Investing Cash Flow(333.78M)248.98M35.81M(136.31M)179.99M
Debt Repayment0(2.2M)1.83M00
Common Stock Issued267.27M8.4M38.39M262.65M1.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M(32.13M)538K3.54M0
Financing Cash Flow268.78M(25.93M)40.75M266.19M1.09M
Effect of Forex Changes00000
Net Change in Cash(108.42M)96.38M(57.72M)(15.43M)5.33M
Free Cash Flow(44.02M)(127.8M)(134.48M)(145.3M)(175.8M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$219.9M
+ D&A$311.0K
+ Stock-Based Comp$36.0M
+ Deferred Tax$0
+ Working Capital$14.1M
- Other Non-Cash-$6.3M
= Operating Cash Flow-$175.8M
- Capex-$49.0K
= Free Cash Flow-$175.8M

Analysis

FY2025 free cash flow is -$175.8M. FCF conversion is 80.0% of net income. Operating cash flow was -$175.8M, with capex of -$49.0K. The largest bridge item is Stock-Based Comp at $36.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 6, 2026

Does CGEM generate free cash flow?

Cullinan Therapeutics, Inc. (CGEM) generated -$175.80M of free cash flow in fiscal 2025.

How much operating cash flow does CGEM produce?

Operating cash flow was -$175.75M, before capital expenditures of $49,000.00.